The Koch Institute’s 14th annual Summer Symposium explored the genetic and epigenetic heterogeneity within tumors that yield diverse cancer phenotypes, such as drug resistance. Speakers highlighted the latest breakthroughs in overcoming clinical challenges in cancer diagnostics and therapy.
![]() |
Signatures of Mutational Processes in Human CancerSir Michael Stratton, PhD View video (with opening remarks from Tyler Jacks and Michael Hemann) |
![]() |
Genetic Features of Subclonal Evolution in Pancreatic CancerChristine A. Iacobuzio-Donahue, MD, PhD |
![]() |
Spatial and Temporal Dynamics of Tumour Evolution: Implications for Drug DevelopmentCharles Swanton, MD, PhD |
![]() |
Tumor Heterogeneity and Drug ResistanceAlice Shaw, MD, PhD |
![]() |
Breast Tumor EvolutionKornelia Polyak, MD, PhD |
![]() |
The Deeper Phenotypes of the Single Cell in Cancer and ImmunityGarry P. Nolan, PhD |
![]() |
Navigating the Phenotypic Landscape of Tumor Heterogeneity at Single-Cell ResolutionDana Pe'er, PhD |
![]() |
Engineering the Cancer GenomeTyler Jacks, PhD |
![]() |
Pediatric Cancer and Genome SimplicityKimberly Stegmaier, MD |
![]() |
High Complexity Barcoding to Study Clonal Dynamics in Response to Cancer TherapyFrank Stegmeier, PhD |
![]() |
The Tumor Microenvironment Drives Heterogeneity in Therapeutic ResponseMichael Hemann, PhD View video (with closing remarks from Tyler Jacks) |
Baxalta US Inc
Janssen Research & Development, LLC
Takeda Oncology
Thermo Fisher Scientific
Agilent Technologies, Inc.
Amgen
Supported by an educational grant from AstraZeneca
Boehringer Ingelheim RCV GmbH & Co KG
Onkaido Therapeutics
Roche
Sanofi
Third Rock Ventures LLC
Alnylam Pharmaceuticals
Atlas Venture
Blueprint Medicines
Cell Signaling Technology, Inc.
Genentech, Inc., a Member of the Roche Group
Merrimack Pharmaceuticals
Mirna Therapeutics
Nature Medicine
Novartis Institutes for BioMedical Research
BioLegend
Cell Press
Cell Signaling
EMD Millipore
Exiqon Inc
IDT
Proteinsimple
Qiagen Inc
Seahorse BioScience
Stemcell
Transnetyx